NCT02460224 - Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | Biotech Hunter

Enrollment

490

Participants

Timeline

Start Date

June 17, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Advanced Solid Tumors

Interventions

DRUG

LAG525

LAG525 was administered via intravenous (i.v.) infusion

DRUG

PDR001

PDR001 was administered via i.v. infusion

Trial Locations (24)

2145

Novartis Investigative Site, Westmead

3000

Novartis Investigative Site, Leuven

3084

Novartis Investigative Site, Heidelberg

10002

Novartis Investigative Site, Taipei

10032

Columbia University Medical Center SC LAG X2101C, New York

10065

Memorial Sloan Kettering Cancer Center SC, New York

20133

Novartis Investigative Site, Milan

27704

Duke Clinical Research Institute SC, Durham

28009

Novartis Investigative Site, Madrid

41124

Novartis Investigative Site, Modena

44805

Novartis Investigative Site, Saint-Herblain Cédex

69120

Novartis Investigative Site, Heidelberg

69373

Novartis Investigative Site, Lyon

77030

University of Texas MD Anderson Cancer Center, Houston

78229

Cancer Therapy and Research Center UT Health Science Center CTRC 2, San Antonio

84112

Huntsman Cancer Institute Huntsman Cancer Institute, Salt Lake City

97080

Novartis Investigative Site, Würzburg

119228

Novartis Investigative Site, Singapore

169610

Novartis Investigative Site, Singapore

T6G 1Z2

Novartis Investigative Site, Edmonton

M5G 2M9

Novartis Investigative Site, Toronto

Unknown

Novartis Investigative Site, Hong Kong

811-1395

Novartis Investigative Site, Fukuoka

08035

Novartis Investigative Site, Barcelona